Review of Clinical Pharmacology and Pharmacokinetics – International Edition – Volume 38 (2024) – Supplementary Issue 2
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, approved for the treatment of diabetes mellitus, have gained attention for their cardioprotective effect. The exact mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Continue reading